CIK 0001388320 · Non-accelerated filer<br>Smaller reporting company
Actinium Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ATNM
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 880378336
- Phone
- (646) 677-3870
- Business address
- 100 PARK AVE., 23RD FLOOR, NEW YORK, NY, 10017
- Former names
- Cactus Ventures, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-31 | O'Loughlin Steve Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −59,066 | 0 | ||
| 2025-03-31 | O'Loughlin Steve Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −107,463 | 0 | ||
| 2025-03-31 | O'Loughlin Steve Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −256,438 | 0 | ||
| 2025-03-31 | O'Loughlin Steve Chief Financial Officer | Returned to the company · Stock Option (Right to Buy) | −253,123 | 0 | ||
| 2024-11-01 | Almenoff June Sherie Director | Grant or award · Stock Option (Right to Buy) | +50,000 | 50,000 | ||
| 2023-12-28 | Nicholson, C. David Director | Grant or award · Stock Option (Right to Buy) | +70,311 | 70,311 | ||
| 2023-12-28 | Steinhart Richard I Director | Grant or award · Stock Option (Right to Buy) | +70,311 | 70,311 | ||
| 2023-12-28 | O'Loughlin Steve Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +253,123 | 253,123 | ||
| 2023-12-28 | Shetty Ajit Director | Grant or award · Stock Option (Right to Buy) | +70,311 | 70,311 | ||
| 2023-12-28 | SETH SANDESH Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +984,367 | 984,367 | ||
| 2023-12-28 | Chell Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +70,311 | 70,311 | ||
| 2022-08-17 | SETH SANDESH Chief Executive Officer | Grant or award | +300,000 | 305,381 | ||
| 2022-07-01 | O'Loughlin Steve Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +256,438 | 256,348 | ||
| 2022-07-01 | Nicholson, C. David Director | Grant or award · Stock Option (Right to Buy) | +72,156 | 72,156 | ||
| 2022-07-01 | Steinhart Richard I Director | Grant or award · Stock Option (Right to Buy) | +72,156 | 72,156 | ||
| 2022-07-01 | Shetty Ajit Director | Grant or award · Stock Option (Right to Buy) | +72,156 | 72,156 | ||
| 2022-07-01 | SETH SANDESH Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +827,366 | 827,366 | ||
| 2022-07-01 | Chell Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +72,156 | 72,156 | ||
| 2021-09-01 | Chell Jeffrey W. Director | Grant or award · Stock Option (Right to Buy) | +18,351 | 18,351 | ||
| 2021-09-01 | Berger Mark Stanley Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +67,164 | 67,164 |
Page 4 of 16 · 316 trades